2024 World Conference on Lung Cancer (WCLC) - Posters-P2.14A.08 Tyrosine Kinase Inhibitors (Alone or in Combination) for the Management of Advanced Thymic Epithelial Tumors (TETs) Among Hispanics

P2.14A.08 Tyrosine Kinase Inhibitors (Alone or in Combination) for the Management of Advanced Thymic Epithelial Tumors (TETs) Among Hispanics

Back to course

Pdf Summary

This document presents a study on the effectiveness of tyrosine kinase inhibitors (TKIs) in treating advanced thymic epithelial tumors (TETs), focusing on Hispanic patients in Latin America. Thymic epithelial tumors are rare cancers with limited treatment options, especially after first-line chemotherapy. The study included 34 patients with confirmed thymic carcinoma, with a median diagnosis age of 52, and 35% of the participants were female. At diagnosis, 97% presented symptoms, and 18% experienced myasthenia gravis. A familial history of cancer was noted in 59% of cases. Disease staging showed most patients were in advanced stages, with 68% at stage IVB.<br /><br />In terms of pathology, CD117 positivity was noted in 66% of cases tested, and molecular characterization showed mutations, with TP53 being the most common in 67% of cases. Lenvatinib was the most frequently administered treatment (61.8%), with sunitinib and everolimus also used. TKIs were primarily used as second-line treatments (62%), leading to a partial response in 15% of patients and disease stabilization in 56%. Progression-free survival (PFS) was a median of 5.88 months, and overall survival (OS) was a median of 53.7 months. Earlier TKI administration (second-line) led to better PFS outcomes compared to later lines of treatment.<br /><br />The study concludes that TKIs are effective as second or subsequent treatments for advanced TETs in Hispanic populations, providing a viable treatment option where standard therapies are limited. The research was based on data from a real-world database, focusing on patient demographics, tumor genomics, and treatment outcomes to evaluate the efficacy and clinical characteristics associated with TKI use, alone or in combination with immunotherapy.

Asset Subtitle

Andres Cardona

Meta Tag

Speaker Andres Cardona

Topic Mesothelioma, Thymoma & Other Thoracic Tumors

Keywords

tyrosine kinase inhibitors

thymic epithelial tumors

Hispanic patients

Latin America

second-line treatment

TP53 mutations

progression-free survival

overall survival

lenvatinib

real-world database